

Supporting information for

Enantiomerically pure 2-aryl(alkyl)-2-trifluoromethylaziridines:


Synthesis and ring opening with selected *O*- and *N*-nucleophiles.

Fabienne Grellepois,^{*} Jean Nonnenmacher, Fabien Lachaud, Charles Portella


Preparation of racemic samples.	2
¹⁹ F, ¹ H and ¹³ C NMR spectra of all new compounds	3-71
Chromatograms of chiral HPLC	72-78


Preparation of racemic samples.


Racemic samples were prepared as described for chiral compounds starting from racemic aldehydes **1a** (for *N*-tosyl derivatives) or **1c** (for *N*-benzyl derivatives). Racemic aldehydes **1a** and **1c** were prepared from ethylbenzoylformate according to the following scheme:





Ref 1: J. Nonnenmacher, F. Massicot, F. Grellepois and C. Portella, *J. Org. Chem.*, 2008, **73**, 7990.
















































































































































































































Hydroxysulfonamide (*R*)-**5a** (Daicel: chiralcel OD-H column, hexane:isopropanol 95:5, flow rate 1 mL.min⁻¹)





N-Benzylamino alcohol (*R*)-**5c** (Daicel: chiralpak IC column, hexane:isopropanol 90:10, flow rate 0,5 mL.min⁻¹)





N-Tosyl aziridine (*S*)-**6a** (Daicel: chiralcel OD-H column, hexane:isopropanol 90:10, flow rate 1 mL.min⁻¹)





Hydroxysulfonamide (*S*)-**7a** (Daicel: chiralpak IC column, hexane:isopropanol 90:10, flow rate 1 mL.min⁻¹)



N-Benzylamino alcohol (*S*)-**7c** (Daicel: chiralpak IC column, hexane:isopropanol 90:10, flow rate 0,5 mL.min⁻¹)



Diamine (*S*)-**8a** (Daicel: chiralpak IC column, hexane:isopropanol 90:10, flow rate 1 mL.min⁻¹)



Disulfonamide (*S*)-**12a** (Daicel: chiralpak IC column, hexane:isopropanol 75:25, flow rate 1 mL.min⁻¹)

